Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

Abstract

Current clinical treatment guidelines recommend cytotoxic chemotherapy, endocrine therapy, or both (with targeted therapy if indicated) for premenopausal women with early-stage breast cancer, depending on the biologic characteristics of the primary tumor. Some of these therapies can induce premature menopause or are specifically designed to suppress ovarian function and reduce circulating estrogen levels. In addition to bone loss associated with low estrogen levels, cytotoxic chemotherapy may have a direct negative effect on bone metabolism. As a result, cancer treatment-induced bone loss poses a significant threat to bone health in premenopausal women with breast cancer. Clinical trials of antiresorptive therapies, such as bisphosphonates, have demonstrated the ability to slow or prevent bone loss in this setting. Current fracture risk assessment tools are based on data from healthy postmenopausal women and do not adequately address the risks associated with breast cancer therapy, especially in younger premenopausal women. We therefore recommend that all premenopausal women with breast cancer be informed about the potential risk of bone loss prior to beginning anticancer therapy. Women who experience amenorrhea should have bone mineral density assessed by dual-energy X-ray absorptiometry and receive regular follow-up to monitor bone health. Regular exercise and daily calcium and vitamin D supplementation are recommended. Women with a Z-score <-2.0 or Z-score ≤-1.0 and/or a 5-10% annual decrease in bone mineral density should be considered for bisphosphonate therapy in addition to calcium and vitamin D supplements.

• Authors: P Hadji, M Gnant, J J Body, N J Bundred, A Brufsky, R E Coleman, T A Guise, A Lipton, M S Aapro
• Journal: Cancer treatment reviews (Cancer Treat Rev) Vol. 38 Issue 6 Pg. 798-806 (Oct 2012) ISSN: 1532-1967 [Electronic] Netherlands
• PMID: 22429722 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2012 Elsevier Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents
• Bone Density Conservation Agents

Topics

• Amenorrhea (chemically induced, epidemiology)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Bone Density Conservation Agents (therapeutic use)
• Clinical Trials as Topic
• Female
• Fractures, Bone (etiology)
• Humans
• Incidence
• Neoplasms (complications, drug therapy)
• Osteoporosis (chemically induced, drug therapy, epidemiology)
• Premenopause
• Risk Assessment